Description : Since DPP-4 inhibitors and metformin improve glycemic control via different albeit potentially complementary mechanisms. Combination therapy with these two agents should provide effective and potentially additive glycemic control. Studies using combination therapy of DPP-4 inhibitors and metformin (as one pill) showed favorable results in glycemic control because of favorable pharmacokinetic characteristics and complementary pharmacodynamic effects, which include enhanced incretin effect, suppressed hepatic glucose production, and improved peripheral insulin sensitivity. Moreover, in general, the combination of this drug into a single tablet improves patients’ compliance and often results in a lower cost of treatment. Indeed several fixed-dose combinations have been developed and/or commercialized - Diabetes Metab Syndr Obes. 2013; 6: 187–195.
Description : Since DPP-4 inhibitors and metformin improve glycemic control via different albeit potentially complementary mechanisms. Combination therapy with these two agents should provide effective and potentially additive glycemic control. Studies using combination therapy of DPP-4 inhibitors and metformin (as one pill) showed favorable results in glycemic control because of favorable pharmacokinetic characteristics and complementary pharmacodynamic effects, which include enhanced incretin effect, suppressed hepatic glucose production, and improved peripheral insulin sensitivity. Moreover, in general, the combination of this drug into a single tablet improves patients’ compliance and often results in a lower cost of treatment. Indeed several fixed-dose combinations have been developed and/or commercialized - Diabetes Metab Syndr Obes. 2013; 6: 187–195.
Description : In a study of 2741 patients on oral (OAD), there was an inverse relationship between OAD adherence and HbA1c; controlling for baseline HbA1c and therapy regimen, each 10% increase in oral diabetes medication adherence was associated with a 0.1% HbA1c decrease (P = 0.0004), suggesting that adherent patients are more likely to achieve glycemic control than the non-adherent ones - Indian Journal of Endocrinology & metabolism 2015, May June 19 (3) The estimated prevalence of 61.3 million in India is expected to rise to 101.2million (65% increase) by 2030 resulting in every fifth person with diabetes in the world will be an Indian - Indian Journal of Endocrinology & Metabolism-2013Volume: 17 Issue: 4 Page: 594-601.
Description : Vildagliptin is an oral anti-diabetic agent that enhances pancreatic islet cell responsiveness to glucose. Approximately 22,000 patients and 7000 patient-years of exposure to Vildagliptin have shown that the agent is well tolerated and efficacious in improving glycemic control in patients with T2DM. Monotherapy trials have shown that significant HbA1c lowering is accompanied by body weight-neutral and lipid-neutral effects, low risk of edema, and low risk of hypoglycemia. These characteristics make Vildagliptin a favorable partner for combination therapy. Studies of Vildagliptin as an add-on to metformin have shown significant improvements in glycemic control (comparable to that of thiazolidinedione add-on), with the combination being well tolerated and associated with low risks for hypoglycemia and adverse effects on weight or lipid levels. Good tolerability and clinically relevant improvements in glycemic control have also been observed with Vildagliptin as an add-on treatment to sulfonylurea, thiazolidinedione, or insulin treatment or in initial combination treatment with pioglitazone. Improved β-cell function and glycemic control have been shown with Vildagliptin in subjects with impaired glucose tolerance and in T2DM patients with mild hyperglycemia, with some evidence in the latter suggesting the potential for modifying disease course- Vasc Health Risk Manag. 2008 Dec; 4(6): 1349-1360
Description : Vildagliptin is an oral anti-diabetic agent that enhances pancreatic islet cell responsiveness to glucose. Approximately 22,000 patients and 7000 patient-years of exposure to Vildagliptin have shown that the agent is well tolerated and efficacious in improving glycemic control in patients with T2DM. Monotherapy trials have shown that significant HbA1c lowering is accompanied by body weight-neutral and lipid-neutral effects, low risk of edema, and low risk of hypoglycemia. These characteristics make Vildagliptin a favorable partner for combination therapy. Studies of Vildagliptin as an add-on to metformin have shown significant improvements in glycemic control (comparable to that of thiazolidinedione add-on), with the combination being well tolerated and associated with low risks for hypoglycemia and adverse effects on weight or lipid levels. Good tolerability and clinically relevant improvements in glycemic control have also been observed with Vildagliptin as an add-on treatment to sulfonylurea, thiazolidinedione, or insulin treatment or in initial combination treatment with pioglitazone. Improved β-cell function and glycemic control have been shown with Vildagliptin in subjects with impaired glucose tolerance and in T2DM patients with mild hyperglycemia, with some evidence in the latter suggesting the potential for modifying disease course- Vasc Health Risk Manag. 2008 Dec; 4(6): 1349-1360.
Description : Vildagliptin is an oral anti-diabetic agent that enhances pancreatic islet cell responsiveness to glucose. Approximately 22,000 patients and 7000 patient-years of exposure to Vildagliptin have shown that the agent is well tolerated and efficacious in improving glycemic control in patients with T2DM. Monotherapy trials have shown that significant HbA1c lowering is accompanied by body weight-neutral and lipid-neutral effects, low risk of edema, and low risk of hypoglycemia. These characteristics make Vildagliptin a favorable partner for combination therapy. Studies of Vildagliptin as an add-on to metformin have shown significant improvements in glycemic control (comparable to that of thiazolidinedione add-on), with the combination being well tolerated and associated with low risks for hypoglycemia and adverse effects on weight or lipid levels. Good tolerability and clinically relevant improvements in glycemic control have also been observed with Vildagliptin as an add-on treatment to sulfonylurea, thiazolidinedione, or insulin treatment or in initial combination treatment with pioglitazone. Improved β-cell function and glycemic control have been shown with Vildagliptin in subjects with impaired glucose tolerance and in T2DM patients with mild hyperglycemia, with some evidence in the latter suggesting the potential for modifying disease course- Vasc Health Risk Manag. 2008 Dec; 4(6): 1349-1360.
Description : Vildagliptin is an oral anti-hyperglycemic agent of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas. Approximately 22,000 patients and 7000 patient-years of exposure to Vildagliptin have shown that the agent is well tolerated and efficacious in improving glycemic control in patients with T2DM. Monotherapy trials have shown that significant HbA1c lowering is accompanied by body weight-neutral and lipid-neutral effects, low risk of edema, and low risk of hypoglycemia. These characteristics make Vildagliptin a favorable partner for combination therapy. Studies of Vildagliptin as an add-on to metformin have shown significant improvements in glycemic control (comparable to that of thiazolidinedione add-on), with the combination being well tolerated and associated with low risks for hypoglycemia and adverse effects on weight or lipid levels. Good tolerability and clinically relevant improvements in glycemic control have also been observed with Vildagliptin as an add-on treatment to sulfonylurea, thiazolidinedione, or insulin treatment or in initial combination treatment with pioglitazone. Improved β-cell function and glycemic control have been shown with Vildagliptin in subjects with impaired glucose tolerance and in T2DM patients with mild hyperglycemia, with some evidence in the latter suggesting the potential for modifying disease course- Vasc Health Risk Manag. 2008 Dec; 4(6): 1349-1360.
Form : Tablets
/ Pack : 10 x 10’s
/ Type : ALU-ALU
Description : This randomized double-blind placebo-controlled multicenter study was conducted in 289 patients who received either nateglinide at doses of 30 mg (n = 51), 60 mg (n = 58), 120 mg (n = 63), or 180 mg (n = 57) or placebo (n = 60) before three main meals for 12 weeks. Levels of HbA1c, fasting plasma glucose (FPG), fructosamine, and plasma lipids were measured at predetermined intervals, and the effects of nateglinide on prandial glucose insulin, C-peptide, and triglyceride levels were measured after a liquid standard meal (Sustacal; Mead Johnson, Evansville, IN). Adverse events and hypoglycemic episodes were recorded. RESULTS: After a liquid meal challenge, nateglinide rapidly increased mealtime insulin levels within 30 min of drug intake and reduced mealtime glucose excursions without affecting triglyceride levels. At study end point, reduction of HbA1c levels was statistically significantly greater with nateglinide at doses of 60, 120, and 180 mg than placebo (-0.45, -0.62, and -0.64%, respectively; P<0.05). The mean level of FPG was significantly reduced versus placebo in the nateglinide 120-mg group only (-1.14 mmol/l P<0.01). Overall, nateglinide was well tolerated. CONCLUSIONS: This study demonstrated that nateglinide improves mealtime and mean glycemic control in a dose-dependent manner by restoring early insulin secretion phase. Nateglinide was well tolerated and is suitable for the treatment of patients with type 2 diabetes- Diabetes Care 2000 Feb; 23(2): 202-207.
View more products with following salts Nateglinide
Repa X-2
So Sweet Sir…. Need Not Sweets
Composition : Repaglinide 2mg
Form : Tablets
/ Pack : 10 x 10’s
/ Type : ALU-ALU
Description : This multinational, open-label study comprised a 6-week run-in period, continuing prestudy antidiabetic medication, followed by a titration period (1–4 weeks) and a 3-month maintenance period. Patients with normal renal function (n = 151) and various degrees of renal impairment (n = 130) were treated with repaglinide (maximal dose of 4 mg, three times daily). Safety and efficacy assessments were performed at baseline (end of run-in) and at the end of study treatment. RESULTS: The type and severity of adverse events during repaglinide treatment were similar to the run-in period. The number of patients with adverse events was not significantly related to renal function during run-in or repaglinide treatment. Percentage of patients with hypoglycemic episodes increased significantly (P = 0.007) with increasing severity of renal impairment during run-in but not during repaglinide treatment (P = 0.074). Metabolic control (HbA1c and fasting blood glucose) with repaglinide was unchanged from that on previous antidiabetic medication. Final repaglinide dose tended to be lower for patients with severe and extreme renal impairment than for patients with less severe renal impairment or normal renal function (P = 0.032).
CONCLUSIONS: Repaglinide has a good safety and efficacy profile in type 2 diabetic patients complicated by renal impairment and is an appropriate treatment choice, even for individuals with more severe degrees of renal impairment- Diabetes Care 2003 Mar; 26(3): 886-891.
View more products with following salts Repaglinide
Repa X-1
So Sweet Sir…. Need Not Sweets
Composition : Repaglinide 1mg
Form : Tablets
/ Pack : 10 x 10’s
/ Type : ALU-ALU
Description : This multinational, open-label study comprised a 6-week run-in period, continuing prestudy antidiabetic medication, followed by a titration period (1–4 weeks) and a 3-month maintenance period. Patients with normal renal function (n = 151) and various degrees of renal impairment (n = 130) were treated with repaglinide (maximal dose of 4 mg, three times daily). Safety and efficacy assessments were performed at baseline (end of run-in) and at the end of study treatment. RESULTS: The type and severity of adverse events during repaglinide treatment were similar to the run-in period. The number of patients with adverse events was not significantly related to renal function during run-in or repaglinide treatment. Percentage of patients with hypoglycemic episodes increased significantly (P = 0.007) with increasing severity of renal impairment during run-in but not during repaglinide treatment (P = 0.074). Metabolic control (HbA1c and fasting blood glucose) with repaglinide was unchanged from that on previous antidiabetic medication. Final repaglinide dose tended to be lower for patients with severe and extreme renal impairment than for patients with less severe renal impairment or normal renal function (P = 0.032). CONCLUSIONS: Repaglinide has a good safety and efficacy profile in type 2 diabetic patients complicated by renal impairment and is an appropriate treatment choice, even for individuals with more severe degrees of renal impairment- Diabetes Care 2003 Mar; 26(3): 886-891.
View more products with following salts Repaglinide
